




# The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy

Sonja Adebahr<sup>1</sup> · Alexander Althaus<sup>2</sup> · Sophia Scharl<sup>3</sup> · Iosif Strouthos<sup>4</sup> · Andrea Farolfi<sup>5</sup> · Francesca Serani<sup>5</sup> · Helena Lanzafame<sup>5</sup> · Christian Trapp<sup>6</sup> · Stefan A. Koerber<sup>7,8</sup> · Jan C. Peeken<sup>9,10,11</sup> · Marco M. E. Vogel<sup>9,10,11</sup> · Alexis Vrachimis<sup>12,13</sup> · Simon K. B. Spohn<sup>1,11,14</sup> · Anca-Ligia Grosu<sup>1,11</sup> · Stephanie G. C. Kroeze<sup>15,16</sup> · Matthias Guckenberger<sup>16</sup> · Stefano Fanti<sup>5</sup> · George Hruby<sup>17</sup> · Louise Emmett<sup>18,19</sup> · Claus Belka<sup>6,11,20</sup> · Nina-Sophie Schmidt-Hegemann<sup>6,20</sup> · Christoph Henkenberens<sup>21</sup> · Daniel M. Aebbersold<sup>2</sup> · Thomas Wiegel<sup>3</sup> · Ali Afshar-Oromieh<sup>22</sup> · Constantinos Zamboglou<sup>1,4,14</sup> · Mohamed Shelan<sup>2</sup> 

Received: 6 August 2023 / Accepted: 8 September 2023 / Published online: 22 September 2023  
© The Author(s) 2023

## Abstract

**Aim** The optimal management for early recurrent prostate cancer following radical prostatectomy (RP) in patients with negative prostate-specific membrane antigen positron-emission tomography (PSMA-PET) scan is an ongoing subject of debate. The aim of this study was to evaluate the outcome of salvage radiotherapy (SRT) in patients with biochemical recurrence with negative PSMA PET finding.

**Methods** This retrospective, multicenter (11 centers, 5 countries) analysis included patients who underwent SRT following biochemical recurrence (BR) of PC after RP without evidence of disease on PSMA-PET staging. Biochemical recurrence-free survival (bRFS), metastatic-free survival (MFS) and overall survival (OS) were assessed using Kaplan-Meier method. Multivariable Cox proportional hazards regression assessed predefined predictors of survival outcomes.

**Results** Three hundred patients were included, 253 (84.3%) received SRT to the prostate bed only, 46 (15.3%) additional elective pelvic nodal irradiation, respectively. Only 41 patients (13.7%) received concomitant androgen deprivation therapy (ADT). Median follow-up after SRT was 33 months (IQR: 20–46 months). Three-year bRFS, MFS, and OS following SRT were 73.9%, 87.8%, and 99.1%, respectively. Three-year bRFS was 77.5% and 48.3% for patients with PSA levels before PSMA-PET  $\leq 0.5$  ng/ml and  $> 0.5$  ng/ml, respectively. Using univariate analysis, the International Society of Urological Pathology (ISUP) grade  $> 2$  ( $p = 0.006$ ), metastatic pelvic lymph nodes at surgery ( $p = 0.032$ ), seminal vesicle involvement ( $p < 0.001$ ), pre-SRT PSA level of  $> 0.5$  ng/ml ( $p = 0.004$ ), and lack of concomitant ADT ( $p = 0.023$ ) were significantly associated with worse bRFS. On multivariate Cox proportional hazards, seminal vesicle infiltration ( $p = 0.007$ ), ISUP score  $> 2$  ( $p = 0.048$ ), and pre SRT PSA level  $> 0.5$  ng/ml ( $p = 0.013$ ) remained significantly associated with worse bRFS.

**Conclusion** Favorable bRFS after SRT in patients with BR and negative PSMA-PET following RP was achieved. These data support the usage of early SRT for patients with negative PSMA-PET findings.

**Keywords** PET negative · PSMA-PET · Prostate cancer · Salvage radiotherapy

## Introduction

The use of postoperative radiotherapy (PORT), alone or combined with androgen deprivation therapy (ADT), is a curative option for patients with adverse risk features and/or biochemical recurrence (BR) following radical prostatectomy (RP) [1, 2]. There has been much debate over the optimal timing for administering this treatment. Although

adjuvant radiation therapy should be considered in high risk patients [3], recent randomized prospective trials and a prospectively planned meta-analysis have provided clear evidence suggesting early salvage radiotherapy (SRT) at low PSA levels as a viable alternative to adjuvant radiotherapy (RT), with similar oncological outcomes and fewer adverse effects [4–7]. The previously mentioned trials included patients with BR who were staged using conventional modalities.

Extended author information available on the last page of the article

With the implementation of PSMA-PET imaging as standard staging examination for primary and recurrent prostate cancer after primary treatment, significant changes in clinical practice have been reached [8]. Various studies reported the superiority of PSMA-PET compared to conventional imaging in detecting lesions for patients with BR after RP [9]. PSMA-PET identifies lesions outside the recommended target volume for SRT in approximately 20% of patients, often also at low PSA levels [10, 11]. When PSMA-PET is conducted before deploying SRT, approximately 50% of patients with a pre-SRT PSA of less than 0.5 ng/ml had PSMA-PET findings [10, 11]. Given the superior sensitivity of PSMA-PET for detecting PC lesions, it is unclear whether patients with PET-negative results might benefit from timely SRT after BR detection. As detection probability in PSMA-PET increases with rising PSA levels [12], an alternative approach could be to postpone SRT in such patients and provide more targeted treatment after localizing the recurrence; however, this strategy needs to be tested prospectively before its clinical implementation. The European Association of Urology (EAU) guidelines, recommends early SRT, even when PET results are negative [13]. Nevertheless, there are currently no prospective studies and limited retrospective data to support these recommendations [14, 15].

We have previously compared the outcome of PSMA-PET guided SRT in 173 patients with negative and 168 patients with positive PSMA-PET findings from an international retrospective database of 1222 patients without significant difference in bRFS in a multivariate analysis, supporting current recommendation of early SRT deployment, independent of PSMA-PET findings. This analysis included very well selected patients without evidence of pathological lymph node metastases or macroscopic residual tumor at surgery (R2). Furthermore, patients who received elective nodal RT and /or ADT had been excluded [16].

In the current analysis, we present outcomes of SRT in a larger cohort of 300 patients with negative PET findings, focusing on biochemical relapse-free survival (bRFS), metastasis-free survival (MFS), and overall survival (OS).

## Materials and methods

### Patients

Data from eleven centers in five countries was analyzed retrospectively, Germany ( $n = 6$ ), Italy ( $n = 1$ ), Australia ( $n = 1$ ), Switzerland ( $n = 2$ ), and Cyprus ( $n = 1$ ). Local ethics committees of participating centers approved this study. Each center collected clinico-pathological features, treatment characteristics, and follow-up data for patients who received PSMA-PET-based SRT for PSA recurrence (a PSA level of 0.1 ng/ml or higher) after RP.

The collected database included 1222 patients treated between August 2013 and June 2020. Patients with PSA persistence after RP, defined as PSA  $\geq 0.1$  ng/ml, and those without RT to the prostate bed were excluded. Additionally, patients with macroscopic recurrence within the prostate bed, evidence of lymph nodes or distant metastases on PSMA-PET scans, were not included in this analysis. The final cohort included 300 patients who received SRT due to BR after RP with a negative macroscopic PSMA-PET scan (Fig. 1).

### Treatment and follow-up

All patients underwent intensity-modulated image-guided SRT to the prostate bed with or without elective pelvic nodal irradiation. Target volume definition, delivered dose, and use of ADT were delivered according to the treating center policy. PSA testing was performed at regular intervals as part of the institutional follow-up protocol. In case of BR after SRT, patients underwent PSMA-PET or conventional imaging to identify the site of clinical recurrence.


### Outcome measures

Primary study endpoint was biochemical recurrence-free survival (bRFS), defined as time from completing SRT to BR (specified as nadir after SRT + 0.2 ng/ml), the last date recorded alive or death from any cause, whichever came first. Secondary endpoints were MFS (defined as interval between SRT initiation and the date of metastasis or death, whichever occurred first) and OS (defined as time from completing SRT to the last date recorded alive or death from any cause). The site of clinical recurrence was assessed according to imaging findings in case of BR after SRT.

### Statistical analysis

All calculations were performed with IBM SPSS Statistics Version 28.0 (IBM Corp., Armonk, NY, USA) or R (Version 4.1.2). Categorical data were presented as frequency and percentages. Normally distributed continuous data were presented as mean and standard deviation (SD), while abnormally distributed continuous data were presented as median and interquartile range (IQR). BRFS, MFS, and OS were estimated with Kaplan–Meier method (log-rank test) and the Cox regression model. Covariates assessed in the univariate Cox regression analysis included the International Society of Urological Pathology (ISUP) grade, seminal vesicle invasion at surgery, resection status (R0–R1), serum values before SRT (PSA before SRT), time gap between surgery and SRT, maximal prescription dose to the prostatic fossa and SRT to elective pelvic lymphatics. Only factors that achieved a  $p$  value  $< 0.1$  in

**Fig. 1** Flowchart shows selection of patients treated with SRT for prostate cancer. *PET* positron emission tomography, *PSA* prostate-specific antigen, *RT* radiotherapy



the univariate analysis were included in the multivariate Cox regression analysis. Hazard ratios (HR) were considered significant when the corresponding 95% confidence interval (95% CI) excluded 1. All t-tests were calculated two-sided. *p* values <0.05 were considered statistically significant. The site of clinical recurrence was assessed descriptively.

## Results

### Patient and treatment baseline characteristics

Patient- and tumor-related characteristics are summarized in Table 1. Median age at SRT was 68 years (range: 47–82 years). Among the 300 patients included, 253 (84.3%) had PSA levels  $\leq 0.5$  ng/ml before starting SRT, and 214 (71.3%) had a dose to the prostatic fossa between of 66 and 70 Gy in 2 Gy per fraction regimen using intensity-modulated image-guided technique for all the patients. As visible in Table 1, the majority of the patients had high-risk features at the time of RP (60.7% ISUP score 3 or higher, 47.6% T3-4 disease). Time from RP to SRT was longer

than 1 year in 57.7% of patients. Of 300 identified patients, the majority (84.3%) received SRT exclusively to the prostate bed, while in 15.3%, elective pelvic nodal irradiation was also used and conducted. Only 41 out of 300 patients (13.7%) received concomitant ADT.

### Oncological outcome(s)

Median follow-up after SRT was 33 months (IQR: 20–46 months), 3-year bRFS, MFS and OS following SRT were 73.9, 87.8%, and 99.1%, respectively (Figs. 2, 3, and 4). Three-year bRFS was 77.5% and 48.3% for patients with PSA levels before PSMA-PET  $\leq 0.5$  ng/ml and  $> 0.5$  ng/ml, respectively (Log-Rank *p* value = 0.003) (Fig. 5). For 222 out of 300 patients (74%) presence and localization of recurrence was reported, 40 of 222 patients (18%) revealed recurrences in follow-up imaging. Following SRT, isolated nodal relapse (21 patients out of 40), predominantly within the pelvis (14 patients out of 40), was the most common pattern of recurrence followed by bone metastasis (10 patients out of 40) (Figure S1).

**Table 1** Patient and treatment characteristics

|  | Total cohort |
|--|--------------|
| Number of patients, <i>n</i>                           | 300          |
| Median age at sRT                                      | 68 (47–82)   |
| pT stage at surgery, <i>n</i> (%)                      |              |
| T2   | 145 (48.3)   |
| T3a  | 103 (34.3)   |
| T3b  | 39 (13)      |
| T4   | 1 (0.3)      |
| Unknown  | 12 (4)       |
| pN stage at surgery, <i>n</i> (%)                      |              |
| Negative   | 221 (73.7)   |
| Positive   | 34 (11.3)    |
| Unknown  | 45 (15)      |
| Resection status in surgery, <i>n</i> (%)              |              |
| R0   | 198 (66)     |
| R1   | 89 (29.7)    |
| R2   | 1 (0.3)      |
| Rx   | 3 (1)        |
| Unknown  | 9 (3)        |
| ISUP grade in surgery, <i>n</i> (%)                    |              |
| 1+2  | 111 (37)     |
| 3  | 102 (34)     |
| 4  | 42 (14)      |
| 5  | 38 (12.7)    |
| Unknown  | 7 (2.3)      |
| The time gap between surgery and sRT, <i>n</i> (%)     |              |
| ≤1 year  | 114 (38)     |
| >1 year  | 173 (57.7)   |
| Unknown  | 13 (4.3)     |
| PSA before sRT, <i>n</i> (%)                           |              |
| ≤ 0.5 ng/dl  | 253 (84.3)   |
| > 0.5 ng/dl  | 47 (15.7)    |
| Dose <sup>a</sup> to the prostatic fossa, <i>n</i> (%) |              |
| <66 Gy   | 34 (11.3)    |
| 66–70 Gy   | 214 (71.3)   |
| >70 Gy   | 48 (16)      |
| Unknown  | 4 (1.3)      |
| sRT to elective pelvic lymphatics, <i>n</i> (%)        |              |
| Yes  | 46 (15.3)    |
| No   | 253 (84.3)   |
| Unknown  | 1 (0.3)      |
| ADT, <i>n</i> (%)                                      |              |
| Yes  | 41 (13.7)    |
| No   | 259 (86.3)   |
| Tracer PET   |              |
| 68Ga-PSMA-11   | 261 (87)     |
| 18F-PSMA-1007  | 20 (6.7)     |
| 18F-rhPSMA-7   | 7 (2.3)      |
| 18F-rhPSMA-7.3   | 11 (3.7)     |
| Other  | 1 (0.3)      |

*IQR* interquartile range, *ISUP* International Society of Urological Pathology, *PSA* prostate-specific antigen, *sRT* salvage radiotherapy, *ADT* androgen deprivation therapy

<sup>a</sup>Dose is given in equivalent dose 2 Gy (EQD2,  $\alpha/\beta = 1.6$  Gy)

## Univariate and multivariate analysis

Among the potential factors able to influence bRFS in this cohort, using the univariate analysis, five factors were significantly associated with decreased bRFS, ISUP score > 2 ( $p = 0.006$ ), presence of positive pelvic lymph nodes at surgery ( $p = 0.032$ ), seminal vesicle infiltration ( $p < 0.001$ ), higher pre-SRT-PSA-level (> 0.5 ng/ml) ( $p = 0.004$ ), and ADT avoidance ( $p = 0.023$ ). Following multivariable Cox proportional hazards, seminal vesicle infiltration ( $p = 0.007$ ), ISUP score > 2 ( $p = 0.048$ ), and pre SRT PSA level (> 0.5 ng/ml) ( $p = 0.013$ ) remained negative predictors for biochemical failure (Table 2).


## Discussion

In this multicenter retrospective analysis, we report on a cohort of 300 patients with BR following RP with no evidence of disease in PSMA-PET scans. After a median follow-up of 33 months 3-year bRFS, MFS and OS following SRT were favorable with a significant difference in the 3-year bRFS for patients with pre-PET-PSA-levels ≤ 0.5 ng/ml and > 0.5 ng/ml, respectively ( $p < 0.003$ ). Although all patients included in this analysis had no evidence of disease in the PSMA-PET scan prior to SRT, biochemical outcome control was comparable to published series reporting on PSMA-PET positive patients [17–19] and consistent with a smaller cohort of 173 patients previously analyzed by our group [16]. Although patients with pathological lymph node metastases revealed significantly worse bRFS in the univariate analysis (not significant in the multivariate setting) and lymph node metastases in the pelvis was the most frequent recurrence site, elective nodal SRT had no significant influence on bRFS, probably due to the limited number of patients receiving nodal RT.

In the study by Meijer et al., improved oncological outcomes for patients who underwent pre-SRT PSMA-PET were reported. One year after SRT, the biochemical progression rate was 8% for patients with pathologic pre-SRT PSMA-PET compared to 21% for those without pre-SRT PSMA-PET [20]. Additionally, Emmett and colleagues showed that PSMA-PET could be a valuable prognostic tool for predicting treatment response to SRT in patients experiencing BR [18].

In a separate publication from our group, Scharl et al. compared directly the outcome of PSMA-PET-guided SRT in negative and positive PSMA-PET patients [16]. The 3-year bRFS was 71.6% in PET-negative cases and 80.8% in local only PET-positive cases in very well selected patients without pathological lymph node metastases or macroscopic residual tumor at surgery (R2). Additionally, SRT was delivered to the prostate bed exclusively and patients

**Fig. 2** Kaplan–Meier curves of biochemical progression-free survival (bPFS) in patients who underwent salvage radiotherapy after radical prostatectomy for patients with biochemical failure who have negative prostate-specific membrane antigen positron-emission tomography




| Patients at risk | 0 month | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | 48 months | BRFS after 3 years | BRFS after 4 years |
|------------------|---------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|--------------------|--------------------|
|                  | 300     | 285      | 245       | 198       | 172       | 139       | 110       | 67        | 95        | 73.9%              | 58.1%              |

who received combined ADT were excluded. The difference in bRFS was significant in univariate ( $p = 0.019$ ) but not multivariate analyses ( $p = 0.366$ ). It might have been expected that based on the negative PET results, a more precise selection of “good risk” patients could be made, resulting in better bRFS. However, results are not superior to those obtained by selecting based solely on PSA levels.

Several publications have previously shown the influence of timing SRT on MFS. In a retrospective analysis involving 1106 patients, Stish et al. observed higher MFS and prostate cancer-specific survival among post-RP patients experiencing BR who underwent SRT at PSA levels of  $\leq 0.5$  ng/ml


compared  $> 0.5$  ng/ml [21]. In a recent JCO publication, Tilki et al. found that patients who underwent SRT at a PSA level greater than 0.25 ng/ml exhibited a significantly higher risk of all-cause mortality compared to SRT at PSA levels of 0.25 ng/ml or lower [22]. Additionally, among patients with PSA level  $> 0.25$  ng/ml, there was a numerically increased risk of prostate cancer-specific mortality. The authors recommended performing PSMA-PET scans and the initiation of SRT before the PSA reaches 0.25 ng/ml. As per our findings, pelvic lymph nodal recurrence was described as rare but predominant site of failure after SRT to the prostate bed [23]. There has been a surge in exploration of adding

**Fig. 3** Kaplan–Meier curves of overall survival (OS) in patients who underwent salvage radiotherapy after radical prostatectomy for patients with biochemical failure who have negative prostate-specific membrane antigen positron-emission tomography



| Patients at risk | 0 month | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | 48 months | OS after 3 years | BRFS after 4 years |
|------------------|---------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|------------------|--------------------|
|                  | 300     | 293      | 264       | 231       | 205       | 170       | 141       | 96        | 69        | 99.1%            | 99.1%              |

**Fig. 4** Kaplan–Meier curves of metastasis-free survival (MFS) in patients who underwent salvage radiotherapy after radical prostatectomy for patients with biochemical failure who have negative prostate-specific membrane antigen positron-emission tomography




| Patients at risk | 0 month | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | 48 months | MFS after 3 years | BRFS after 4 years |
|------------------|---------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-------------------|--------------------|
|                  | 300     | 231      | 201       | 166       | 139       | 109       | 94        | 72        | 58        | 87.8%             | 86.6%              |

pelvic nodal radiation to prostate bed treatment. The RTOG 0534 (SPPORT) randomized study enrolled patients with either persistently detectable or initially undetectable and rising PSA levels following RP. These patients received RT to the prostate bed only, to the prostate bed and short-term ADT or both pelvic lymph node RT and short-term ADT, respectively. There was no significant OS difference reported among the three arms. However, for RT to the pelvic node and prostate bed combined with short-term ADT, an improvement in the freedom from disease progression (FFDP) was reported [24]. In our multicenter analysis, RT treatment protocols were not standardized. Only 15.3% of patients received RT to pelvic nodes according to their respective institutional policies. The inclusion of pelvic

nodal irradiation into the target volume might potentially reduce the likelihood of regional failure; however, no significant benefit could be seen in our analysis.

It is important to note that staging in the SPPORT trial was mainly based on conventional imaging. Due to the lack of high-level evidence, inclusion of pelvic nodes into RT field for all patients under undergoing SRT due to BR in the PSMA PET era cannot be considered as a standard of care especially with the absence of OS benefit in the SPPORT trial. Better identification of patients at higher risk to develop pelvic node metastasis after RP who might profit from elective pelvic irradiation simultaneously with prostate bed is crucial. Additionally, offering metastasis directed therapy or whole pelvic irradiation in case of

**Fig. 5** Kaplan–Meier curve representing the bRFS rates (log-rank test) of patients who received salvage radiotherapy following radical prostatectomy with biochemical failure who have negative prostate-specific membrane antigen positron-emission tomography. The patients are divided into two groups based on their PSA levels: those with PSA levels equal to or below 0.5 ng/ml, and those with PSA levels above 0.5 ng/ml



| Subgroups          | 0 month | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | 48 months | Log-Rank P-value | BRFS after 3 years | BRFS after 4 years |
|--------------------|---------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|------------------|--------------------|--------------------|
| PSA_PET ≤ 0.5ng/ml | 253     | 240      | 210       | 176       | 154       | 123       | 97        | 61        | 37        | 0.003            | 77.5%              | 60.7%              |
| PSA_PET > 0.5ng/ml | 47      | 45       | 35        | 22        | 18        | 166       | 13        | 7         | 3         |                  | 48.3%              | 43.0%              |

**Table 2** Uni- and multivariate Cox regression on bRFS

| Variable  | Univariate               |                  | Multivariate             |                |
|---|--------------------------|------------------|--------------------------|----------------|
|   | HR (95% CI)              | <i>p</i> value   | HR (95% CI)              | <i>p</i> value |
| SVI (yes vs. no)  | <b>0.318 (0.19–0.54)</b> | <b>&lt;0.001</b> | <b>0.44 (0.25–0.799)</b> | <b>0.007</b>   |
| R status (R0 vs. R1 + R2 + Rx)                                | 1.073 (0.666–1.728)      | 0.772            |                          |                |
| ISUP (1 + 2 vs. 3 + 4 + 5)                                    | <b>0.49 (0.295–0.81)</b> | <b>0.006</b>     | <b>0.59(0.34–0.996)</b>  | <b>0.048</b>   |
| PLNS (yes vs. no)   | <b>0.56(0.324–0.951)</b> | <b>0.032</b>     | 0.82(0.45–1.5)           | 0.506          |
| TS-sRT ( $\leq 1$ year vs. $> 1$ year)                        | 1.205 (0.78–1.86)        | 0.403            |                          |                |
| Pre-SRT PSA ( $\leq 0.5$ ng/dl vs. $> 0.5$ ng/dl)             | <b>0.47 (0.282–0.79)</b> | <b>0.004</b>     | <b>0.503(0.29–0.86)</b>  | <b>0.013</b>   |
| ADT administration (yes vs. no)                               | <b>0.519(0.296–0.91)</b> | <b>0.023</b>     | 0.71 (0.39–1.3)          | 0.263          |
| sRT dose to the prostatic fossa ( $\leq 66$ Gy vs. $> 66$ Gy) | 0.89 (0.43–1.87)         | 0.776            |                          |                |
| Elective RT to LN (yes vs. no)                                | 0.865 (0.493–1.515)      | 0.611            |                          |                |

HR hazard ratio, CI confidence interval, SVI seminal vesicle invasion in surgery, R status resection status in surgery, ISUP International Society of Urological Pathology, PLNS pelvic lymph nodes in surgery, Pre-SRT PSA prostate-specific antigen before the salvage radiotherapy, TS-sRT time gap between surgery and salvage radiotherapy, sRT salvage radiotherapy, ADT androgen deprivation therapy; RT radiotherapy; LN lymph nodes. Bold: significant

macroscopic nodal recurrence detected via PSMA PET remains an open question while the results of the PEACE-V STORM trial are still pending [25, 26].

The combination of ADT with RT in the postoperative setting and its effect on oncological outcomes has been a matter of debate. Recently, results of prospective phase III randomized trials were published, demonstrating the benefit of the combined treatment [27, 28]. In the above mentioned SPPORT trial the addition of ADT lead to more benefit regarding FFDP than elective pelvic nodal RT [27]. In the RTOG 9601, 771 men were randomly assigned to SRT plus bicalutamide for 2 years or SRT alone. The first interim results at a median follow-up of 7 years were negative for OS; however, the latest report at a median follow-up of 12.6 years demonstrated an actuarial 10-year OS of 82% for SRT plus ADT and 78% for SRT plus placebo [21]. Similarly, the GETUG-AFU 16 randomized men with BR after RP to SRT alone versus SRT combined with 6 months of LHRH agonists, showing that SRT combined with short-term ADT significantly reduced the risk of progression and death [28]. Although the optimal duration of ADT in combination with SRT is not established, the data presented at European Society for Medical Oncology (ESMO) Congress 2022 from Radicals HD trial reported that 24 months was superior to 6 month of ADT, improving time to salvage ADT and MFS. Conversely, the comparison between 6 month of ADT and no ADT demonstrated that the former improved time to salvage ADT but had no significant impact on MFS [29]. In our cohort, only 16.9% of patients received concurrent ADT, and the duration of ADT varied based on institutional policy. However, it is reasonable to anticipate that an increase in bRFS may be achieved by implementing more intensified ADT utilization.

Various ongoing trials are exploring the issue of the impact of PSMA-guided SRT compared to conventional SRT on both survival and quality of life outcomes with the possibility of offering tailored treatment strategies based on the PSMA PET finding [30–35]. Moreover, the integration of novel biomarkers holds potential in enabling a personalized evaluation of risk in the postoperative setting. It has been demonstrated that a genomic classifier score can predict the postoperative risk of developing metastases [22, 36–38]. This may further refine the criteria for choosing optimal patients for SRT and nuance the selection of systemic treatment [39]. Furthermore, we have previously reported on the development and validation of a nomogram for prediction of freedom from biochemical failure (FFBF) after PSMA-PET-based sRT [40].

Limitations of this study include those common to retrospective studies, such as unequal distribution of risk factors and potential selection bias. Additionally, definitions of SRT varied between treatment centers and pre-SRT PSA levels were recorded as categorical rather than numerical values, which limited the accuracy of multivariate analysis adjustments. There was also a marked numerical imbalance between those receiving SRT to prostate bed alone and those who also received additional elective nodal RT and/or concomitant ADT.

## Conclusion

In conclusion, the study demonstrates favorable bRFS outcomes following SRT in patients with BR and negative PSMA-PET post RP. These findings endorse early SRT utilization in cases of BR and negative PSMA-PET, while stressing the necessity for randomized controlled trials to

determine the viability before omitting early SRT based on negative PSMA-PET.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00259-023-06438-3>.

**Funding** Open access funding provided by University of Bern

**Data availability** The datasets used and/or analyzed during the current study are available as MS Excel files (.xlsx) from the corresponding author upon reasonable request.

## Declarations

**Ethics approval** Local ethics committees of participating centers approved this study.

**Consent for publication** Not applicable.

**Competing interests** SA receives payment from the Federal Ministry of Education and Research (BMBF), Decade against Cancer. The other authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References


- Bottke D, Bartkowiak D, Siegmann A, Thamm R, Böhmer D, Budach V, Wiegel T. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. *Prostate Cancer Prostatic Dis*. 2019;22(2):344–9. <https://doi.org/10.1038/s41391-018-0112-3>.
- Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. *J Clin Oncol*. 2016;34(30):3648–54. <https://doi.org/10.1200/JCO.2016.67.9647>.
- Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Mohamad O, Cowan JE, Feng FY, Carroll PR, Trock BJ, Partin AW, D'Amico AV. Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. *J Clin Oncol*. 2021;39(20):2284–93. <https://doi.org/10.1200/JCO.20.03714>.
- Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche MS, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihoum M, Soulié M, Richaud P. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. *Lancet Oncol*. 2020;21(10):1341–52. [https://doi.org/10.1016/S1470-2045\(20\)30454-X](https://doi.org/10.1016/S1470-2045(20)30454-X).
- Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes MR, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, MKB P, Tierney JF, ARTISTIC Meta-analysis Group. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. *Lancet*. 2020;396(10260):1422–31. [https://doi.org/10.1016/S0140-6736\(20\)31952-8](https://doi.org/10.1016/S0140-6736(20)31952-8).
- Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. *Lancet Oncol*. 2020;21. [https://doi.org/10.1016/S1470-2045\(20\)30456-3](https://doi.org/10.1016/S1470-2045(20)30456-3).
- Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. *The Lancet*. 2020;396. [https://doi.org/10.1016/S0140-6736\(20\)31553-1](https://doi.org/10.1016/S0140-6736(20)31553-1).
- Sabbagh A, Mohamad O, Lichter KE, Hope TA. Management of patients with recurrent and metachronous oligometastatic prostate cancer in the era of PSMA PET. *Cancers (Basel)*. 2022;14. <https://doi.org/10.3390/cancers14246194>.
- Treglia G, Pereira Mestre R, Ferrari M, Bosetti DG, Pascale M, Oikonomou E, et al. Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis. *Am J Nucl Med Mol Imaging*. 2019;9.
- Zamboglou C, Strouthos I, Sahlmann J, Farolfi A, Serani F, Medici F, et al. Metastasis-free survival and patterns of distant metastatic disease after prostate-specific membrane antigen positron emission tomography (PSMA-PET)-guided salvage radiation therapy in recurrent or persistent prostate cancer after prostatectomy. *Int J Radiat Oncol Biol Phys [Internet]*. 2022 [cited 2023 May 9];113:1015–24. Available from: <https://pubmed.ncbi.nlm.nih.gov/35659629/>.
- Bouchelouche K, Choyke PL, Capala J. Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. *Discov Med*. 2010;9(44):55–61.
- Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients. *Eur J Nucl Med Mol Imaging [Internet]*. 2021 [cited 2023 May 22];48:2925–34. Available from: <https://pubmed.ncbi.nlm.nih.gov/33543325/>.
- Combes AD, Palma CA, Calopedos R, Wen L, Woo H, Fulham M, et al. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. *Diagnostics*. 2022;12. <https://doi.org/10.3390/diagnostics12112594>.
- Bianchi L, Ceci F, Costa F, Balestrazzi E, Droghetti M, Piazza P, et al. The impact of PSMA-PET on oncologic control in prostate cancer patients who experienced PSA persistence or recurrence. *Cancers (Basel)*. 2023;15. <https://doi.org/10.3390/cancers15010247>.
- Morawitz J, Kirchner J, Lakes J, Bruckmann NM, Mamlins E, Hiester A, et al. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications. *Eur J Radiol*. 2021;136. <https://doi.org/10.1016/j.ejrad.2021.109556>.
- Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H, et al. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study. *Radiother Oncol [Internet]*. 2023;184:109678. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0167814023002165>. Accessed 22 May 2023.
- Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, et al. Outcome after PSMA PET/CT based salvage



- radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis. *J Nucl Med* [Internet]. 2019 [cited 2023 May 10];60:227–33. Available from: <https://pubmed.ncbi.nlm.nih.gov/30002108/>.
18. Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts JA, et al. 3-year freedom from progression after 68Ga-PSMA PET/CT-Triaged management in men with biochemical recurrence after radical prostatectomy: Results of a prospective multicenter trial. *J Nucl Med*. 2020;61. <https://doi.org/10.2967/jnumed.119.235028>.
  19. Shelan M, Odermatt S, Bojaxhiu B, Nguyen DP, Thalmann GN, Aebbersold DM, et al. Disease control with delayed salvage radiotherapy for macroscopic local recurrence following radical prostatectomy. *Front Oncol*. 2019;9. <https://doi.org/10.3389/fonc.2019.00012>.
  20. Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, et al. Prostate-specific membrane antigen positron emission tomography/computed tomography is associated with improved oncological outcome in men treated with salvage radiation therapy for biochemically recurrent prostate cancer. *Eur Urol Oncol*. 2022;5. <https://doi.org/10.1016/j.euo.2022.01.001>.
  21. Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. *J Clin Oncol* [Internet]. 2016 [cited 2023 May 22];34:3864–71. Available from: <https://pubmed.ncbi.nlm.nih.gov/27480153/>.
  22. Tilki D, Chen M-H, Wu J, Huland H, Graefen M, Mohamad O, et al. Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. *J Clin Oncol* [Internet]. 2023 [cited 2023 May 22];41. Available from: <https://pubmed.ncbi.nlm.nih.gov/36857638/>.
  23. Brand DH, Parker JI, Dearnaley DP, Eeles R, Huddart R, Khoo V, et al. Patterns of recurrence after prostate bed radiotherapy. *Radiother Oncol*. 2019;141
  24. Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. *The Lancet*. 2022;399. [https://doi.org/10.1016/S0140-6736\(21\)01790-6](https://doi.org/10.1016/S0140-6736(21)01790-6).
  25. PEACE V: Salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM) | *ClinicalTrials.gov* [Internet]. [cited 2023 Sep 8]. Available from: <https://clinicaltrials.gov/study/NCT0356924126>.
  26. Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Turriaga A, et al. The multicenter, randomized, phase 2 PEACE V-STORM trial: defining the best salvage treatment for oligorecurrent nodal prostate cancer metastases. *Eur Urol Focus*. 2021.
  27. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. *New Engl J Med*. 2017;376. <https://doi.org/10.1056/nejmoa1607529>.
  28. Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. *Lancet Oncol*. 2019;20. [https://doi.org/10.1016/S1470-2045\(19\)30486-3](https://doi.org/10.1016/S1470-2045(19)30486-3).
  29. Parker CC, Clarke N, Cook A, Catton C, Cross WR, Kynaston H, et al. LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031). *Ann Oncol*. 2022;33. <https://doi.org/10.1016/j.annonc.2022.08.064>.
  30. Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT after radical prostatectomy - *ClinicalTrials.gov* [Internet]. [cited 2023 May 10]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03582774>.
  31. PSMA-PET Guided radiotherapy - *ClinicalTrials.gov* [Internet]. [cited 2023 May 10]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03525288>.
  32. Testing the addition of the drug relugolix to the usual radiation therapy for advanced-stage prostate cancer - full text view - *ClinicalTrials.gov* [Internet]. [cited 2023 May 10]. Available from: [https://clinicaltrials.gov.translate.google.com/ct2/show/NCT05053152?x\\_tr\\_sl=en&x\\_tr\\_tl=ar&x\\_tr\\_hl=ar&x\\_tr\\_pto=sc](https://clinicaltrials.gov.translate.google.com/ct2/show/NCT05053152?x_tr_sl=en&x_tr_tl=ar&x_tr_hl=ar&x_tr_pto=sc).
  33. Treating prostate cancer that has come back after surgery with apalutamide and targeted radiation using PET/CT imaging - *ClinicalTrials.gov* [Internet]. [cited 2023 May 10]. Available from: <https://clinicaltrials.gov/ct2/show/NCT04423211>.
  34. PSMA guided approach for biochemical relapse after prostatectomy-PSICHE - *ClinicalTrials.gov* [Internet]. [cited 2023 Sep 8]. Available from: <https://classic.clinicaltrials.gov/ct2/show/NCT05022914>.
  35. Stereotactic salvage radiotherapy for macroscopic prostate bed recurrence after prostatectomy—a prospective observational study - *ClinicalTrials.gov* [Internet]. [cited 2023 Sep 8]. Available from: <https://classic.clinicaltrials.gov/ct2/show/NCT05455736?term=NCT05455736&draw=2&rank=1>.
  36. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HAD, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. *Lancet Oncol* [Internet]. 2016 [cited 2023 May 22];17:1612–20. Available from: <http://www.thelancet.com/article/S1470204516304910/fulltext>.
  37. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choerung V, Feng FY, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. *J Clin Oncol*. 2015;33:944–51.
  38. Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, et al. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. *Prostate Cancer Prostatic Dis*. 2016;19(3):277–82. Available from: <https://www.nature.com/articles/pcan201615>.
  39. Dal Pra A, Ghadjar P, Hayoz S, Liu VYT, Spratt DE, Thompson DJS, et al. Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy – an ancillary study of the SAKK 09/10 randomized clinical trial. *Ann Oncol*. 2022;33.
  40. Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, et al. Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer. *JAMA Netw Open* [Internet]. 2023;6:e2314748–8. Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805173>.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Authors and Affiliations

Sonja Adebahr<sup>1</sup> · Alexander Althaus<sup>2</sup> · Sophia Scharl<sup>3</sup> · Iosif Strouthos<sup>4</sup> · Andrea Farolfi<sup>5</sup> · Francesca Serani<sup>5</sup> · Helena Lanzafame<sup>5</sup> · Christian Trapp<sup>6</sup> · Stefan A. Koerber<sup>7,8</sup> · Jan C. Peeken<sup>9,10,11</sup> · Marco M. E. Vogel<sup>9,10,11</sup> · Alexis Vrachimis<sup>12,13</sup> · Simon K. B. Spohn<sup>1,11,14</sup> · Anca-Ligia Grosu<sup>1,11</sup> · Stephanie G. C. Kroeze<sup>15,16</sup> · Matthias Guckenberger<sup>16</sup> · Stefano Fanti<sup>5</sup> · George Hruby<sup>17</sup> · Louise Emmett<sup>18,19</sup> · Claus Belka<sup>6,11,20</sup> · Nina-Sophie Schmidt-Hegemann<sup>6,20</sup> · Christoph Henkenberens<sup>21</sup> · Daniel M. Aebersold<sup>2</sup> · Thomas Wiegel<sup>3</sup> · Ali Afshar-Oromieh<sup>22</sup> · Constantinos Zamboglou<sup>1,4,14</sup> · Mohamed Shelan<sup>2</sup> 

✉ Mohamed Shelan  
mohamed.shelan@insel.ch

<sup>1</sup> Department of Radiation Oncology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK), partner site DKTK-Freiburg, Freiburg, Germany

<sup>2</sup> Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland

<sup>3</sup> Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany

<sup>4</sup> Department of Radiation Oncology, German Oncology Center, European University Cyprus, Nicosia, Cyprus

<sup>5</sup> Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

<sup>6</sup> Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany

<sup>7</sup> Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany

<sup>8</sup> Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany

<sup>9</sup> Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany

<sup>10</sup> Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum, Munich, Germany

<sup>11</sup> German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany

<sup>12</sup> Department of Nuclear Medicine, German Oncology Center, University Hospital of the European University, Limassol, Cyprus

<sup>13</sup> C.A.R.I.C. Cancer Research & Innovation Center, Limassol, Cyprus

<sup>14</sup> Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany

<sup>15</sup> Radiation Oncology Center KSA-KSB, Canton Hospital of Aarau, Aarau, Switzerland

<sup>16</sup> Department of Radiation Oncology, University Hospital Zürich, University of Zurich, Zurich, Switzerland

<sup>17</sup> Department of Radiation Oncology, Royal North Shore Hospital – University of Sydney, Sydney, Australia

<sup>18</sup> Department of Theranostics and Nuclear medicine, St Vincent's Hospital Sydney, Sydney, Australia

<sup>19</sup> St Vincent's Clinical School, University of New South Wales, Sydney, Australia

<sup>20</sup> Bavarian Cancer Research Center (BZKF), Munich, Germany

<sup>21</sup> Department of Radiotherapy and Special Oncology, Medical School Hannover, Hanover, Germany

<sup>22</sup> Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland